rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-561-569rsp-3245Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESМаркеры воспаления при ревматических заболеванияхInflammatory markers in rheumatic diseaseshttps://orcid.org/0000-0003-3057-9175АвдееваА. С.AvdeevaA. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202225122022606561–569Copyright © Авдеева А.С., 20222022Авдеева А.С.Avdeeva A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3245

Иммуновоспалительные ревматические заболевания (ИВРЗ) – это большая группа патологических состояний, в основе которых лежит нарушение иммунологической толерантности к собственным тканям, ведущее к воспалению и необратимым органным повреждениям. Лабораторная диагностика ИВРЗ включает определение широкого спектра биомаркеров на клеточном и гуморальном уровнях (аутоантител, белков острой фазы воспаления, цитокинов, маркеров повреждения эндотелия, компонентов системы комплемента, иммуноглобулинов, криоглобулинов, субпопуляций лимфоцитов, показателей костного метаболизма, маркеров апоптоза, генетических маркеров и др.). Одним из ведущих аспектов лабораторной диагностики ИВРЗ является исследование уровня маркеров воспаления в крови (скорости оседания эритроцитов, С-реактивного белка (СРБ), сывороточного амилоидного белка А (САА), ферритина, прокальцитонина, аполипопротеина АI, кальпротектина и др.). Анализ маркеров воспаления позволяет оценить активность болезни, характер прогрессирования и прогноз хронического воспалительного процесса, а также эффективность проводимой терапии. В обзоре представлены последние данные о роли таких наиболее часто изучаемых маркеров воспаления, как СРБ, САА и ферритин.

Immune-mediated rheumatic diseases (IMRDs) are a broad group of pathological conditions based on impaired immunological tolerance to one’s own tissues leading to inflammation and irreversible organ damage. Laboratory diagnosis of IMRDs includes a wide range of biomarkers (autoantibodies, acute phase proteins, cytokines, markers of endothelial damage, components of the complement system, immunoglobulins, cryoglobulins, lymphocyte subpopulations, indicators of bone metabolism, apoptosis markers, genetic markers, etc). One of the leading aspects of laboratory diagnosis of IMRDs is the study of the level of inflammation markers in the blood (erythrocyte sedimentation rate, C-reactive protein (CRP), serum amyloid protein (CAA), ferritin, procalcitonin, apolipoprotein AI, calprotectin, etc). The analysis of inflammation markers makes it possible to assess the disease activity, the nature of the progression and the prognosis of the outcomes of a chronic inflammatory process, as well as the effectiveness of the therapy. The review presents the latest data on the role of the most frequently studied inflammatory markers such as CRP, CAA and ferritin.

иммуновоспалительные ревматические заболеваниямаркеры воспаленияС-реактивный белоксывороточный амилоидный белок Аферритинimmune-mediated rheumatic diseasesinflammatory markersC-reactive proteinserum amyloid protein AferritinРабота выполнена за счет средств бюджетного финансирования на выполнение государственного задания по теме 1021051402790-6.ReferencesMcGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297Насонов ЕЛ. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2018;56(Прил 4): 19-27. doi: 10.14412/1995-4484-2018-19-27Nasonov EL. The role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(Suppl 4):19-27 (In Russ.)]. doi: 10.14412/1995-4484-2018-19-27Насонов ЕЛ, Александрова ЕН. Современные стандарты лабораторной диагностики ревматических заболеваний: клинические рекомендации. М.:ЗАО БиоХимМак;2006.Nasonov EL, Alexandrova EN. Modern standards of laboratory diagnostics of rheumatic diseases: Clinical recommendations. Moscow: ZAO BioKhimMak;2006 (In Russ.)].Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, et al.; IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases. Cutting edge diagnostics in rheumatology: The role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum. 2004;51(2): 291-298. doi: 10.1002/art.20229Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, et al.; IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases. Cutting edge diagnostics in rheumatology: The role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum. 2004;51(2): 291-298. doi: 10.1002/art.20229Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004;50(6):1709-1720. doi: 10.1002/art.20344Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004;50(6):1709-1720. doi: 10.1002/art.20344Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004;50(7):2048-2065. doi: 10.1002/art.20345Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004;50(7):2048-2065. doi: 10.1002/art.20345Dayer E, Dayer JM, Roux-Lombard P. Primer: The practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol. 2007;3(9):512-520. doi: 10.1038/ncprheum0572Dayer E, Dayer JM, Roux-Lombard P. Primer: The practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol. 2007;3(9):512-520. doi: 10.1038/ncprheum0572Насонов ЕЛ, Насонова ВА (ред.). Ревматология: Национальное руководство. М.:ГЭОТАР-Медиа;2008. [Nasonov EL, Nasonova VA (eds). Rheumatology: National guidelines. Moscow:GEOTAR-Media;2008 (In Russ.)].Насонов ЕЛ, Насонова ВА (ред.). Ревматология: Национальное руководство. М.:ГЭОТАР-Медиа;2008. [Nasonov EL, Nasonova VA (eds). Rheumatology: National guidelines. Moscow:GEOTAR-Media;2008 (In Russ.)].Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013;56:131-142. doi: 10.1007/s12026-013-8384-0Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013;56:131-142. doi: 10.1007/s12026-013-8384-0Du Clos TW, Mold C. C-reactive protein. Immunol Res. – 2004;30(3):261–77. doi: 10.1385/IR:30:3:261Du Clos TW, Mold C. C-reactive protein. Immunol Res. – 2004;30(3):261–77. doi: 10.1385/IR:30:3:261Newling M, Sritharan L, van der Ham AJ, Hoepel W, Fiechter RH, de Boer L, et al. C-reactive protein promotes inflammation through FcγR-induced glycolytic reprogramming of human macrophages. J Immunol. 2019;203(1):225-235. doi: 10.4049/jimmunol.1900172Newling M, Sritharan L, van der Ham AJ, Hoepel W, Fiechter RH, de Boer L, et al. C-reactive protein promotes inflammation through FcγR-induced glycolytic reprogramming of human macrophages. J Immunol. 2019;203(1):225-235. doi: 10.4049/jimmunol.1900172Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456(7224):989-992. doi: 10.1038/nature07468Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456(7224):989-992. doi: 10.1038/nature07468Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242(2):237-239. doi: 10.1016/0014-5793(89)80476-4Castell JV, Gómez-Lechón MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 1989;242(2):237-239. doi: 10.1016/0014-5793(89)80476-4Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis. J Scleroderma Relat Disord. 2017;2:1-5. doi: 10.5301/jsrd.5000265Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis. J Scleroderma Relat Disord. 2017;2:1-5. doi: 10.5301/jsrd.5000265Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. doi: 10.3389/fimmu.2018.00754Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. doi: 10.3389/fimmu.2018.00754Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K, Eisenhardt SU. Targeting C-reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm. 2015;2015:372432. doi: 10.1155/2015/372432Thiele JR, Zeller J, Bannasch H, Stark GB, Peter K, Eisenhardt SU. Targeting C-reactive protein in inflammatory disease by preventing conformational changes. Mediators Inflamm. 2015;2015:372432. doi: 10.1155/2015/372432McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, et al. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of C-reactive protein and its conformational changes. Front Immunol. 2018;9:1351. doi: 10.3389/fimmu.2018.01351McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, et al. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of C-reactive protein and its conformational changes. Front Immunol. 2018;9:1351. doi: 10.3389/fimmu.2018.01351Cho IJ, Choi KH, Oh CH, Hwang YC, Jeong IK, Ahn KJ, et al. Effects of C-reactive protein on bone cells. Life Sci. 2016;145:1-8. doi: 10.1016/j.lfs.2015.12.021Cho IJ, Choi KH, Oh CH, Hwang YC, Jeong IK, Ahn KJ, et al. Effects of C-reactive protein on bone cells. Life Sci. 2016;145:1-8. doi: 10.1016/j.lfs.2015.12.021Jia ZK, Li HY, Liang YL, Potempa LA, Ji SR, Wu Y. Monomeric C-reactive protein binds and neutralizes receptor activator of NF-κB ligand-induced osteoclast differentiation. Front Immunol. 2018;9:234. doi: 10.3389/fimmu.2018.00234Jia ZK, Li HY, Liang YL, Potempa LA, Ji SR, Wu Y. Monomeric C-reactive protein binds and neutralizes receptor activator of NF-κB ligand-induced osteoclast differentiation. Front Immunol. 2018;9:234. doi: 10.3389/fimmu.2018.00234Насонов ЕЛ, Чичасова НВ, Имаметдинова ГР. Методы оценки поражения суставов, активности заболевания и функционального состояния больных ревматоидным артритом: методическое пособие для врачей. М.;2001.Nasonov EL, Chichasova NV, Imametdinova GR. Methods for assessing joint injury, disease activity and functional status of patients with rheumatoid arthritis: Methodical guidelines for physicians. Moscow; 2001 (In Russ.)].Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013;2013:183653. doi: 10.1155/2013/183653Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013;2013:183653. doi: 10.1155/2013/183653Vanier A, Smolen JS, Allaart CF, Van Vollenhoven R, Verschueren P, Vastesaeger N, et al. An updated matrix to predict rapid radio graphic progression of early rheumatoid arthritis patients: Pooled analyses from several databases. Rheumatology (Oxford). 2020;59(8):1842-1852. doi: 10.1093/rheumatology/kez542Vanier A, Smolen JS, Allaart CF, Van Vollenhoven R, Verschueren P, Vastesaeger N, et al. An updated matrix to predict rapid radio graphic progression of early rheumatoid arthritis patients: Pooled analyses from several databases. Rheumatology (Oxford). 2020;59(8):1842-1852. doi: 10.1093/rheumatology/kez542Авдеева АС, Панасюк ЕЮ, Александрова ЕН, Насонов ЕЛ. Оценка клинической эффективности терапии тоцилизумабом с использованием индексов DAS 28, SDAI, CDAI и новых критериев ремиссии EULAR/ACR 2011 у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(2):20-24. doi: 10.14412/1995-4484-2012-1268Avdeyeva AS, Panasyuk EYu, Aleksandrova EN, Nasonov EL. Evaluation of the clinical efficiency of tocilizumab therapy, by using DAS 28, SDAI, CDAI indices and new 2011 EULAR/ACR remission criteria in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012; 50(2):20-24 (In Russ.)]. doi: 10.14412/1995-4484-2012-1268Agca R, Hopman LHGA, Laan KJC, van Halm VP, Peters MJL, Smulders YM, et al. Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: A 15-year longitudinal study. J Rheumatol. 2020;47(3):316-324. doi: 10.3899/jrheum.180726Agca R, Hopman LHGA, Laan KJC, van Halm VP, Peters MJL, Smulders YM, et al. Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: A 15-year longitudinal study. J Rheumatol. 2020;47(3):316-324. doi: 10.3899/jrheum.180726Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524-1529. doi: 10.1136/annrheumdis2011-200726Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524-1529. doi: 10.1136/annrheumdis2011-200726Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis. 2015;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann Rheum Dis. 2015;74(2):326-332. doi: 10.1136/annrheumdis-2014-205675Pujades-Rodriguez M, Duyx B, Thomas SL, Stogiannis D, Rahman A, Smeeth L, et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: A population record-linkage cohort study in England. PLoS One. 2016;11(3):e0151245. doi: 10.1371/journal.pone.0151245Pujades-Rodriguez M, Duyx B, Thomas SL, Stogiannis D, Rahman A, Smeeth L, et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: A population record-linkage cohort study in England. PLoS One. 2016;11(3):e0151245. doi: 10.1371/journal.pone.0151245Cooksey R, Brophy S, Kennedy J, Gutierrez FF, Pickles T, Davies R, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367-373. doi: 10.1016/j.semarthrit.2018.03.005Cooksey R, Brophy S, Kennedy J, Gutierrez FF, Pickles T, Davies R, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367-373. doi: 10.1016/j.semarthrit.2018.03.005England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ. 2018;361:k1036. doi: 10.1136/bmj.k1036Aday AW, Ridker PM. Targeting residual inflammatory risk: A shifting paradigm for atherosclerotic disease. Front Cardiovasc Med. 2019;6:16. doi: 10.3389/fcvm.2019.00016Aday AW, Ridker PM. Targeting residual inflammatory risk: A shifting paradigm for atherosclerotic disease. Front Cardiovasc Med. 2019;6:16. doi: 10.3389/fcvm.2019.00016Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495. doi: 10.7326/0003-4819-151-7-200910060-00009Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:483-495. doi: 10.7326/0003-4819-151-7-200910060-00009Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320. doi: 10.1056/NEJMoa1107477Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320. doi: 10.1056/NEJMoa1107477Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. – 2009;55(2):229-238. doi: 10.1373/clinchem.2008.108886Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. – 2009;55(2):229-238. doi: 10.1373/clinchem.2008.108886Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, JuanBabot JO, Iborra E, et al. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke. 2006;37(5):1200-1204. doi: 10.1161/01.STR.0000217386.37107.beKrupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, JuanBabot JO, Iborra E, et al. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke. 2006;37(5):1200-1204. doi: 10.1161/01.STR.0000217386.37107.beBadimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430. doi: 10.3389/fimmu.2018.00430Badimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018;9:430. doi: 10.3389/fimmu.2018.00430Molins B, Peña E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol. 2008;28(12):2239-2246. doi: 10.1161/ATVBAHA.108.174359Molins B, Peña E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol. 2008;28(12):2239-2246. doi: 10.1161/ATVBAHA.108.174359Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive protein in atherosclerotic lesions: Its origin and pathophysiological significance. Am J Pathol. 2005;167(4):1139-1148. doi: 10.1016/S0002-9440(10)61202-3Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive protein in atherosclerotic lesions: Its origin and pathophysiological significance. Am J Pathol. 2005;167(4):1139-1148. doi: 10.1016/S0002-9440(10)61202-3Habersberger J, Strang F, Scheichl A, Htun N, Bassler N, Merivirta RM, et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res. 2012;96(1):64-72. doi: 10.1093/cvr/cvs237Habersberger J, Strang F, Scheichl A, Htun N, Bassler N, Merivirta RM, et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res. 2012;96(1):64-72. doi: 10.1093/cvr/cvs237Melnikov I, Kozlov S, Saburova O, Zubkova E, Guseva O, Domogatsky S, et al. CRP is transported by monocytes and monocytederived exosomes in the blood of patients with coronary artery disease. Biomedicines. 2020;8(10):435. doi: 10.3390/biomedicines8100435Melnikov I, Kozlov S, Saburova O, Zubkova E, Guseva O, Domogatsky S, et al. CRP is transported by monocytes and monocytederived exosomes in the blood of patients with coronary artery disease. Biomedicines. 2020;8(10):435. doi: 10.3390/biomedicines8100435Zha Z, Cheng Y, Cao L, Qian Y, Liu X, Guo Y, et al. Monomeric CRP aggravates myocardial injury after myocardial infarction by polarizing the macrophage to pro-inflammatory phenotype through JNK signaling pathway. J Inflamm Res. 2021;14:7053-7064. doi: 10.2147/JIR.S316816Zha Z, Cheng Y, Cao L, Qian Y, Liu X, Guo Y, et al. Monomeric CRP aggravates myocardial injury after myocardial infarction by polarizing the macrophage to pro-inflammatory phenotype through JNK signaling pathway. J Inflamm Res. 2021;14:7053-7064. doi: 10.2147/JIR.S316816Jakuszko K, Krajewska M, Kościelska-Kasprzak K, Myszka M, Sebastian A, Gniewek K, et al. Antibodies against monomeric C-reactive protein – A promising biomarker of lupus nephritis? Clin Biochem. 2017;50(13-14):756-762. doi: 10.1016/j.clinbiochem.2017.03.010Jakuszko K, Krajewska M, Kościelska-Kasprzak K, Myszka M, Sebastian A, Gniewek K, et al. Antibodies against monomeric C-reactive protein – A promising biomarker of lupus nephritis? Clin Biochem. 2017;50(13-14):756-762. doi: 10.1016/j.clinbiochem.2017.03.010Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol. 2011;38(1):29-35. doi: 10.3899/jrheum.100346Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol. 2011;38(1):29-35. doi: 10.3899/jrheum.100346Pandey PK, Swami A, Biswas TK, Thakuria R. Prevalence of metabolic syndrome in treatment naïve rheumatoid arthritis and correlation with disease parameters. Arch Rheumatol. 2016;32:46-52. doi: 10.5606/ArchRheumatol.2017.5949Pandey PK, Swami A, Biswas TK, Thakuria R. Prevalence of metabolic syndrome in treatment naïve rheumatoid arthritis and correlation with disease parameters. Arch Rheumatol. 2016;32:46-52. doi: 10.5606/ArchRheumatol.2017.5949Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62(11):3173-3182. doi: 10.1002/art.27629Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62(11):3173-3182. doi: 10.1002/art.27629Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-2112. doi: 10.1002/art.23600Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-2112. doi: 10.1002/art.23600Attar SM. Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity. Saudi Med J. 2015;36:685-691. doi: 10.15537/smj.2015.6.10557Attar SM. Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity. Saudi Med J. 2015;36:685-691. doi: 10.15537/smj.2015.6.10557Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4(2):e001588. doi: 10.1161/JAHA.114.001588Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4(2):e001588. doi: 10.1161/JAHA.114.001588Gan L, He Y, Liu L, Ou Q, Lin J. Association of serum lipids with autoantibodies and inflammatory markers in rheumatoid arthritis patients. Clin Chim Acta. 2018;486:282-290. doi: 10.1016/j.cca.2018.08.028Gan L, He Y, Liu L, Ou Q, Lin J. Association of serum lipids with autoantibodies and inflammatory markers in rheumatoid arthritis patients. Clin Chim Acta. 2018;486:282-290. doi: 10.1016/j.cca.2018.08.028Ursini F, Russo E, D’Angelo S, Arturi F, Hribal ML, D’Antona L, et al. Prevalence of undiagnosed diabetes in rheumatoid arthritis: An OGTT study. Medicine (Baltimore). 2016;95(7):e2552. doi: 10.1097/MD.0000000000002552Ursini F, Russo E, D’Angelo S, Arturi F, Hribal ML, D’Antona L, et al. Prevalence of undiagnosed diabetes in rheumatoid arthritis: An OGTT study. Medicine (Baltimore). 2016;95(7):e2552. doi: 10.1097/MD.0000000000002552Ruscitti P, Ursini F, Cipriani P, Ciccia F, Liakouli V, Carubbi F, et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a crosssectional study. Medicine (Baltimore). 2017;96(34):e7896. doi: 10.1097/MD.0000000000007896Ruscitti P, Ursini F, Cipriani P, Ciccia F, Liakouli V, Carubbi F, et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a crosssectional study. Medicine (Baltimore). 2017;96(34):e7896. doi: 10.1097/MD.0000000000007896Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848-854. doi: 10.1136/annrheumdis-2016-209954Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848-854. doi: 10.1136/annrheumdis-2016-209954Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531. doi: 10.1001/jama.2011.878Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531. doi: 10.1001/jama.2011.878Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019;14(1):e0210459. doi: 10.1371/journal.pone.0210459Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019;14(1):e0210459. doi: 10.1371/journal.pone.0210459Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Mendy A, Forno E, Niyonsenga T, Gasana J. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J. 2018;12:1891-1899. doi: 10.1111/crj.12752Mendy A, Forno E, Niyonsenga T, Gasana J. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J. 2018;12:1891-1899. doi: 10.1111/crj.12752Kang HK, Kim K, Lee H, Jeong BH, Koh WJ, Park HY. COPD assessment test score and serum C-reactive protein levels in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2016;11:3137-3143. doi: 10.2147/COPD.S118153Kang HK, Kim K, Lee H, Jeong BH, Koh WJ, Park HY. COPD assessment test score and serum C-reactive protein levels in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2016;11:3137-3143. doi: 10.2147/COPD.S118153Silva DR, Gazzana MB, Knorst MM. C-reactive protein levels in stable COPD patients: A case-control study. Int J Chron Obstruct Pulmon Dis. 2015;10:1719-1725. doi: 10.2147/COPD.S87015Silva DR, Gazzana MB, Knorst MM. C-reactive protein levels in stable COPD patients: A case-control study. Int J Chron Obstruct Pulmon Dis. 2015;10:1719-1725. doi: 10.2147/COPD.S87015Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403-1412. doi: 10.1164/rccm.201411-1950OCDoyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191(12):1403-1412. doi: 10.1164/rccm.201411-1950OCLow CA, Cunningham AL, Kao AH, Krishnaswami S, Kuller LH, Wasko MC. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol. 2009;81(2):131-134. doi: 10.1016/j.biopsycho.2009.02.003Low CA, Cunningham AL, Kao AH, Krishnaswami S, Kuller LH, Wasko MC. Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis. Biol Psychol. 2009;81(2):131-134. doi: 10.1016/j.biopsycho.2009.02.003Kojima M, Kojima T, Suzuki S, Oguchi T, Oba M, Tsuchiya H, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(8):1018-1024. doi: 10.1002/art.24647Kojima M, Kojima T, Suzuki S, Oguchi T, Oba M, Tsuchiya H, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(8):1018-1024. doi: 10.1002/art.24647Figueiredo-Braga M, Cornaby C, Cortez A, Bernardes M, Terroso G, Figueiredo M, et al. Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J Immunol Res. 2018;2018:5954897. doi: 10.1155/2018/5954897Figueiredo-Braga M, Cornaby C, Cortez A, Bernardes M, Terroso G, Figueiredo M, et al. Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J Immunol Res. 2018;2018:5954897. doi: 10.1155/2018/5954897Takata S, Wada H, Tamura M, Koide T, Higaki M, Mikura SI, et al. Kinetics of C-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times. Biomarkers. 2011;16(6):530-535. doi: 10.3109/1354750X.2011.607189Takata S, Wada H, Tamura M, Koide T, Higaki M, Mikura SI, et al. Kinetics of C-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times. Biomarkers. 2011;16(6):530-535. doi: 10.3109/1354750X.2011.607189Targonska-Stepniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm. 2014;2014:793628. doi: 10.1155/2014/793628Targonska-Stepniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm. 2014;2014:793628. doi: 10.1155/2014/793628Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363-369. doi: 10.1016/j.bbrc.2003.12.096Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363-369. doi: 10.1016/j.bbrc.2003.12.096Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137-143. doi: 10.3109/14397595.2013.854048Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137-143. doi: 10.3109/14397595.2013.854048Migita K, Koga T, Komori A, Torigoshi T, Maeda Y, Izumi Y, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol. 2011;38(11):2309-2317. doi: 10.3899/jrheum.101362Migita K, Koga T, Komori A, Torigoshi T, Maeda Y, Izumi Y, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol. 2011;38(11):2309-2317. doi: 10.3899/jrheum.101362Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, et al. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol. 2010;184(11):6427-6437. doi: 10.4049/jimmunol.0902941Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, et al. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol. 2010;184(11):6427-6437. doi: 10.4049/jimmunol.0902941Connolly M, Veale DJ, Fearon U. Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis. Ann Rheum Dis. 2011;70(7):1296-1303. doi: 10.1136/ard.2010.142240Connolly M, Veale DJ, Fearon U. Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis. Ann Rheum Dis. 2011;70(7):1296-1303. doi: 10.1136/ard.2010.142240Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol. 2001;166(4):2801-2807. doi: 10.4049/jimmunol.166.4.2801Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol. 2001;166(4):2801-2807. doi: 10.4049/jimmunol.166.4.2801O’Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50(6):1788-1799. doi: 10.1002/art.20301O’Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50(6):1788-1799. doi: 10.1002/art.20301Satomura K, Torigoshi T, Koga T, Maeda Y, Izumi Y, Jiuchi Y, et al. Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes. Mod Rheumatol. 2013;23(1):28-35. doi: 10.1007/s10165-012-0630-0Satomura K, Torigoshi T, Koga T, Maeda Y, Izumi Y, Jiuchi Y, et al. Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes. Mod Rheumatol. 2013;23(1):28-35. doi: 10.1007/s10165-012-0630-0Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204(12):2803-2812. doi: 10.1084/jem.20071397Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204(12):2803-2812. doi: 10.1084/jem.20071397Lucherini OM, Lopalco G, Cantarini L, Emmi G, Lopalco A, Venerito V, et al. Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet’s disease. Immunol Lett. 2018;201:38-44. doi: 10.1016/j.imlet.2018.10.013Lucherini OM, Lopalco G, Cantarini L, Emmi G, Lopalco A, Venerito V, et al. Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet’s disease. Immunol Lett. 2018;201:38-44. doi: 10.1016/j.imlet.2018.10.013Migita K, Koga T, Satomura K, Izumi M, Torigoshi T, Maeda Y, et al. Serum amyloid A triggers the mosodium urate-mediated mature interleukin-1β production from human synovial fibroblasts. Arthritis Res Ther. 2012;14(3):R119. doi: 10.1186/ar3849Migita K, Koga T, Satomura K, Izumi M, Torigoshi T, Maeda Y, et al. Serum amyloid A triggers the mosodium urate-mediated mature interleukin-1β production from human synovial fibroblasts. Arthritis Res Ther. 2012;14(3):R119. doi: 10.1186/ar3849Migita K, Izumi Y, Fujikawa K, Agematsu K, Masumoto J, Jiuchi Y, et al. Dysregulated mature IL-1β production in familial Mediterranean fever. Rheumatology (Oxford). 2015;54(4):660-665. doi: 10.1093/rheumatology/keu359Migita K, Izumi Y, Fujikawa K, Agematsu K, Masumoto J, Jiuchi Y, et al. Dysregulated mature IL-1β production in familial Mediterranean fever. Rheumatology (Oxford). 2015;54(4):660-665. doi: 10.1093/rheumatology/keu359Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186(11):6119-6128. doi: 10.4049/jimmunol.1002843Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J Immunol. 2011;186(11):6119-6128. doi: 10.4049/jimmunol.1002843Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94(1):154-162. doi: 10.1093/cvr/cvs089Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 2012;94(1):154-162. doi: 10.1093/cvr/cvs089Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20(3):763-772. doi: 10.1161/01.atv.20.3.763Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20(3):763-772. doi: 10.1161/01.atv.20.3.763Zhao Y, Zhou S, Heng CK. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(7):1645-1650. doi: 10.1161/ATVBAHA.106.137455Zhao Y, Zhou S, Heng CK. Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(7):1645-1650. doi: 10.1161/ATVBAHA.106.137455Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2008;295(6):H2399-Р2408. doi: 10.1152/ajpheart.00238.2008Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2008;295(6):H2399-Р2408. doi: 10.1152/ajpheart.00238.2008Migita K, Yamasaki S, Shibatomi K, Ida H, Kita M, Kawakami A, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol. 2001;123(3):408-411. doi: 10.1046/j.1365-2249.2001.01472.xMigita K, Yamasaki S, Shibatomi K, Ida H, Kita M, Kawakami A, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immunol. 2001;123(3):408-411. doi: 10.1046/j.1365-2249.2001.01472.xMagy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B. Cellular events associated with the initial phase of AA amyloidogenesis: Insights from a human monocyte model. Amyloid. 2007;14(1):51-63. doi: 10.1080/13506120601116575Magy N, Benson MD, Liepnieks JJ, Kluve-Beckerman B. Cellular events associated with the initial phase of AA amyloidogenesis: Insights from a human monocyte model. Amyloid. 2007;14(1):51-63. doi: 10.1080/13506120601116575Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 2012;64(4):1035-1045. doi: 10.1002/art.33455Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum. 2012;64(4):1035-1045. doi: 10.1002/art.33455Shen C, Sun XG, Liu N, Mu Y, Hong CC, Wei W, et al. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Mol Med Rep. 2015;11(2):1528-1534. doi: 10.3892/mmr.2014.2804Shen C, Sun XG, Liu N, Mu Y, Hong CC, Wei W, et al. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Mol Med Rep. 2015;11(2):1528-1534. doi: 10.3892/mmr.2014.2804Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983;42(6):665-667. doi: 10.1136/ard.42.6.665Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis. 1983;42(6):665-667. doi: 10.1136/ard.42.6.665Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol. 2000;27(1):58-63.Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol. 2000;27(1):58-63.Yoo J, Lee SK, Lim M, Sheen D, Choi EH, Kim SA. Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):119. doi: 10.1186/s13075-017-1334-9Yoo J, Lee SK, Lim M, Sheen D, Choi EH, Kim SA. Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):119. doi: 10.1186/s13075-017-1334-9Hwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL Jr, Moreland LW. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016;18(1):108. doi: 10.1186/s13075-016-1009-yHwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL Jr, Moreland LW. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016;18(1):108. doi: 10.1186/s13075-016-1009-yWild N, Karl J, Grunert VP, Schmitt RI, Garczarek U, Krause F, et al. Diagnosis of rheumatoid arthritis: Multivariate analysis of biomarkers. Biomarkers. 2008;13(1):88-105. doi: 10.1080/13547500701669410Wild N, Karl J, Grunert VP, Schmitt RI, Garczarek U, Krause F, et al. Diagnosis of rheumatoid arthritis: Multivariate analysis of biomarkers. Biomarkers. 2008;13(1):88-105. doi: 10.1080/13547500701669410Targońska-Stępniak B, Dryglewska M, Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients. Pharmacol Rep. 2010;62(4):719-725. doi: 10.1016/s1734-1140(10)70329-7Targońska-Stępniak B, Dryglewska M, Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients. Pharmacol Rep. 2010;62(4):719-725. doi: 10.1016/s1734-1140(10)70329-7Ma MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):158. doi: 10.1186/s13075-020-02240-wMa MHY, Defranoux N, Li W, Sasso EH, Ibrahim F, Scott DL, et al. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):158. doi: 10.1186/s13075-020-02240-wBoeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. ACPA-negative RA consists of subgroups: Patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res Ther. 2019;21(1):121. doi: 10.1186/s13075-019-1902-2Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM. ACPA-negative RA consists of subgroups: Patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res Ther. 2019;21(1):121. doi: 10.1186/s13075-019-1902-2Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol. 2014;175(2):208-214. doi: 10.1111/cei.12234Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol. 2014;175(2):208-214. doi: 10.1111/cei.12234Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013;52(7):1214-1219. doi: 10.1093/rheumato logy/kes381Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013;52(7):1214-1219. doi: 10.1093/rheumato logy/kes381Kobayashi T, Yokoyama T, Ito S, Kobayashi D, Yamagata A, Okada M, et al. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab. J Periodontol. 2014;85(11):1480-1488. doi: 10.1902/jop.2014.140194Kobayashi T, Yokoyama T, Ito S, Kobayashi D, Yamagata A, Okada M, et al. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab. J Periodontol. 2014;85(11):1480-1488. doi: 10.1902/jop.2014.140194Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):178. doi: 10.1186/ar3503Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):178. doi: 10.1186/ar3503Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, et al. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Res Ther. 2020;22(1):70. doi: 10.1186/s13075-020-02163-6Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, et al. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Res Ther. 2020;22(1):70. doi: 10.1186/s13075-020-02163-6Moreira AC, Mesquita G, Gomes MS. Ferritin: An inflmmatory player keeping iron at the core of pathogen-host interactions, Microorganisms. 2020;8(4):589. doi: 10.3390/microorganisms8040589Moreira AC, Mesquita G, Gomes MS. Ferritin: An inflmmatory player keeping iron at the core of pathogen-host interactions, Microorganisms. 2020;8(4):589. doi: 10.3390/microorganisms8040589Harrison PM, Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161-203. doi: 10.1016/0005-2728(96)00022-9Harrison PM, Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161-203. doi: 10.1016/0005-2728(96)00022-9Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al. Ferritin – From iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778. doi: 10.1016/j.jaut.2021.102778Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al. Ferritin – From iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778. doi: 10.1016/j.jaut.2021.102778Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J. 1972;4(5834):206-208. doi: 10.1136/bmj.4.5834.206Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J. 1972;4(5834):206-208. doi: 10.1136/bmj.4.5834.206Birgegård G, Hällgren R, Killander A, Strömberg A, Venge P, Wide L. Serum ferritin during infection. A longitudinal study. Scand J Haematol. 1978;21(4):333-340. doi: 10.1111/j.1600-0609.1978.tb00374.xBirgegård G, Hällgren R, Killander A, Strömberg A, Venge P, Wide L. Serum ferritin during infection. A longitudinal study. Scand J Haematol. 1978;21(4):333-340. doi: 10.1111/j.1600-0609.1978.tb00374.xWeiss G, Ganz T, Goodnough LT. Anemia of inflmmation. Blood. 2019;133:40-50. doi: 10.1056/NEJMra1804281Weiss G, Ganz T, Goodnough LT. Anemia of inflmmation. Blood. 2019;133:40-50. doi: 10.1056/NEJMra1804281Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30:84-89. doi: 10.1016/j.jaut.2007.11.003Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30:84-89. doi: 10.1016/j.jaut.2007.11.003Sharif K, Vieira Borba V, Zandman-Goddard G, Shoenfeld Y. Eppur Si Muove: Ferritin is essential in modulating inflammation. Clin Exp Immunol. 2018;191(2):149-150. doi: 10.1111/cei.13069Sharif K, Vieira Borba V, Zandman-Goddard G, Shoenfeld Y. Eppur Si Muove: Ferritin is essential in modulating inflammation. Clin Exp Immunol. 2018;191(2):149-150. doi: 10.1111/cei.13069Cragg SJ, Wagstaff M, Worwood M. Detection of a glycosylated subunit in human serum ferritin. Biochem J. 1981;199:565-571. doi: 10.1042/bj1990565Cragg SJ, Wagstaff M, Worwood M. Detection of a glycosylated subunit in human serum ferritin. Biochem J. 1981;199:565-571. doi: 10.1042/bj1990565Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997;90(12):4979-4986.Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997;90(12):4979-4986.Fahmy M, Young P. Modulation of iron metabolism in monocyte cell line U937 by inflmmatory cytokines: Changes in transferrin uptake, iron handling and ferritin mRNA, Biochem J. 1993; 296(Pt 1):175-181. doi: 10.1042/bj2960175Fahmy M, Young P. Modulation of iron metabolism in monocyte cell line U937 by inflmmatory cytokines: Changes in transferrin uptake, iron handling and ferritin mRNA, Biochem J. 1993; 296(Pt 1):175-181. doi: 10.1042/bj2960175Kotze MJ, van Velden DP, van Rensburg SJ, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: New insights for clinical application. EJIFCC. 2009;20(2):108-123.Kotze MJ, van Velden DP, van Rensburg SJ, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: New insights for clinical application. EJIFCC. 2009;20(2):108-123.Simcox JA, McClain DA. Iron and diabetes risk. Cell Metabol. 2013;17(3):329-341. doi: 10.1016/j.cmet.2013.02.007Simcox JA, McClain DA. Iron and diabetes risk. Cell Metabol. 2013;17(3):329-341. doi: 10.1016/j.cmet.2013.02.007El Osta R, Grandpre N, Monnin N, Hubert J, Koscinski I. Hypogonadotropic hypogonadism in men with hereditary hemochromatosis. Basic Clin Androl. 2017;27:13. doi: 10.1186/s12610-017-0057-8El Osta R, Grandpre N, Monnin N, Hubert J, Koscinski I. Hypogonadotropic hypogonadism in men with hereditary hemochromatosis. Basic Clin Androl. 2017;27:13. doi: 10.1186/s12610-017-0057-8Chacon AH, Morrison B, Hu S. Acquired hemochromatosis with pronounced pigment deposition of the upper eyelids. J Clin Aesthet Dermatol. 2013;6:44-46.Chacon AH, Morrison B, Hu S. Acquired hemochromatosis with pronounced pigment deposition of the upper eyelids. J Clin Aesthet Dermatol. 2013;6:44-46.Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009;23(3):95-104. doi: 10.1016/j.blre.2008.08.001Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009;23(3):95-104. doi: 10.1016/j.blre.2008.08.001Plays M, Müller S, Rodriguez R. Chemistry and biology of ferritin. Metallomics. 2021;13(5):mfab021. doi: 10.1093/mtomcs/mfab021Plays M, Müller S, Rodriguez R. Chemistry and biology of ferritin. Metallomics. 2021;13(5):mfab021. doi: 10.1093/mtomcs/mfab021Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci. 2002;115(Pt 10):2165-2177. doi: 10.1242/jcs.115.10.2165Thompson KJ, Fried MG, Ye Z, Boyer P, Connor JR. Regulation, mechanisms and proposed function of ferritin translocation to cell nuclei. J Cell Sci. 2002;115(Pt 10):2165-2177. doi: 10.1242/jcs.115.10.2165Üsküdar Cansu D, Üsküdar Teke H, Cansu GB, Korkmaz C. Evaluation of hyperferritinemia causes in rheumatology practice: A retrospective, single-center experience. Rheumatol Int. 2021;41(9):1617-1624. doi: 10.1007/s00296-021-04935-yÜsküdar Cansu D, Üsküdar Teke H, Cansu GB, Korkmaz C. Evaluation of hyperferritinemia causes in rheumatology practice: A retrospective, single-center experience. Rheumatol Int. 2021;41(9):1617-1624. doi: 10.1007/s00296-021-04935-yAbe E, Arai M. Synovial fluid ferritin in traumatic hemarthrosis, rheumatoid arthritis and osteoarthritis. Tohoku J Exp Med. 1992;168(3):499-505. doi: 10.1620/tjem.168.499Abe E, Arai M. Synovial fluid ferritin in traumatic hemarthrosis, rheumatoid arthritis and osteoarthritis. Tohoku J Exp Med. 1992;168(3):499-505. doi: 10.1620/tjem.168.499Vanarsa K, Ye Y, Han J, Xie C, Mohan C, Wu T. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res Ther. 2012;14(4):R182. doi: 10.1186/ar4012Vanarsa K, Ye Y, Han J, Xie C, Mohan C, Wu T. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res Ther. 2012;14(4):R182. doi: 10.1186/ar4012Beyan E, Beyan C, Demirezer A, Ertuğrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol. 2003;32(4):225-228. doi: 10.1080/03009740310003712Beyan E, Beyan C, Demirezer A, Ertuğrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol. 2003;32(4):225-228. doi: 10.1080/03009740310003712Mehta B, Efthimiou P. Ferritin in adult-onset Still’s disease: Just a useful innocent bystander? Int J Inflmm. 2012;2012:298405. doi: 10.1155/2012/298405Mehta B, Efthimiou P. Ferritin in adult-onset Still’s disease: Just a useful innocent bystander? Int J Inflmm. 2012;2012:298405. doi: 10.1155/2012/298405Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease, Ann Rheum Dis. 2006;65:564-572. doi: 10.1136/ard.2005.042143Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease, Ann Rheum Dis. 2006;65:564-572. doi: 10.1136/ard.2005.042143Di Benedetto P, Cipriani P, Iacono D, Pantano I, Caso F, Emmi G, et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS One. 2020;15(7):e0235326. doi: 10.1371/journal.pone.0235326Di Benedetto P, Cipriani P, Iacono D, Pantano I, Caso F, Emmi G, et al. Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS One. 2020;15(7):e0235326. doi: 10.1371/journal.pone.0235326

The authors declare that there are no conflicts of interest present.